## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average burden								
1	hours nor resnance.	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Aryeh Jason					2. Issuer Name <b>and</b> Ticker or Trading Symbol NABI BIOPHARMACEUTICALS NABI								(Che	ck all app	ionship of Reporting all applicable) Director		n(s) to Is 10% O		
(Last) 34 SUMI	(I MER RD.	First)	(Middle)		3. Da			t Trans	nsaction (Month/Day/Year)							Officer (give title below)		Other (spec below)	
(Street) GREENWICH CT 06831 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year) 03/16/2010							Line	) 【 Forn Forn	al or Joint/Group Filing (Check Applicable orm filed by One Reporting Person orm filed by More than One Reporting erson					
		Tab	le I - Nor	า-Deriv	ative	Sec	curitie	s Ac	quired,	Dis	posed o	f, or E	Benef	iciall	y Own	ed			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,			3. Transaction Code (Instr. 8) 4. Securitie Disposed (5)			Of (D) (	Instr. 3		Report	ties cially Following ed	6. Owne Form: D (D) or In (I) (Instr	oirect odirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	V	Amount	(A) (D)	or F	Price	(Instr.	ction(s) 3 and 4)			
Common Stock														37	371,420 <sup>(1)</sup>			Indirect <sup>(1)</sup>	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ersion Date Execution Date, if any (Month/Day/Year) ative			Transaction Code (Instr. B)  5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. : and 4)  Amount or Number of Title Shares		r. 3	Price of erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owi For Dire or Ii (I) (I	nership m: ect (D) ndirect Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## **Explanation of Responses:**

1. On March 16, 2010, the Reporting Person filed a Form 4 reporting a sale of 600 shares of common stock on March 12, 2010, which ultimately was not completed. After giving effect to the reversal of this sale, as of March 12, 2010, the Reporting Person (i) directly owned 17,000 shares, and (ii) indirectly owned 354,420 shares through his relationship with JALAA Equities, LP, JLV Investments, LP, the Jason Aryeh Trust, the Jason Aryeh 2003 Family Trust, and the Jason Aryeh IRA (collectively, the "Aryeh Entities"). Mr. Aryeh disclaims beneficial ownership of all securities held through the Aryeh Entities, except to the extent of any indirect pecuniary interest he may have therein.

## Remarks:

James E. Dawson, as attorney-

03/23/2010

in-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.